Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma

Published:2008-01 Issue:7 Volume:49 Page:1329-1336
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Kuruvilla John,Pintilie Melania,Tsang Richard,Nagy Tracy,Keating Armand,Crump Michael

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428190802108870

Reference41 articles.

1. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

2. THE HUMAN THYMUS CONTAINS A NOVEL POPULATION OF B LYMPHOCYTES

3. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

4. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors and clinical survival outcome in patients with primary mediastinal diffuse large B-cell lymphoma in rituximab era: A population-based study;Medicine;2024-02-23

2. Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital;Clinical Lymphoma Myeloma and Leukemia;2024-01

3. Updates in the Management of Primary Mediastinal B Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-12

4. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up;Blood Advances;2023-09-13

5. Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS;Frontiers in Oncology;2023-06-15